Annual Financials for Century Therapeutics Inc.
Fiscal year is January-December. All values USD millions. |
| 2019 | 2020 | 2021 | 2022 |
5-year trend |
Sales/Revenue
|
- | - | - | - | 5.2M | |
Sales Growth |
- | - | - | - | - | |
Cost of Goods Sold (COGS) incl. D&A |
- | 249,000 | 1.4M | 4.58M | 10.07M | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
- | 249,000 | 1.4M | 4.58M | 10.07M | |
Depreciation |
- | 249,000 | 1.4M | 4.58M | 10.07M | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | - | 463.05% | 226.82% | 119.79% | |
Gross Income |
- | (249,000) | (1.4M) | (4.58M) | (4.87M) | |
Gross Income Growth |
- | - | -463.05% | -226.82% | -6.33% | |
Gross Profit Margin |
- | - | - | - | -93.71% | NA |
|
| 2019 | 2020 | 2021 | 2022 |
5-year trend |
SG&A Expense |
- | 19.78M | 47.77M | 90.3M | 118.96M | |
Research & Development |
- | 14.27M | 39.68M | 75.65M | 97.17M | |
Other SG&A |
- | 5.52M | 8.09M | 14.65M | 21.79M | |
SGA Growth |
- | - | 141.48% | 89.02% | 31.74% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | 225.95M | 4.72M | - | 10M | |
EBIT after Unusual Expense |
- | (245.98M) | (53.9M) | - | (133.83M) | |
Non Operating Income/Expense |
- | 1.21M | 704,000 | 377,000 | 4.42M | |
Non-Operating Interest Income |
- | - | - | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | 381,000 | 1.28M | 1.43M | |
Interest Expense Growth |
- | - | - | 234.65% | 12.16% | |
Gross Interest Expense |
- | - | 381,000 | 1.28M | 1.43M | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
- | (244.77M) | (53.58M) | (95.78M) | (130.84M) | |
Pretax Income Growth |
- | - | 78.11% | -78.78% | -36.60% | |
Pretax Margin |
- | - | - | - | -2,516.66% | NA |
Income Tax |
- | - | - | 43,000 | 91,000 | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | 86,000 | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | 5,000 | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
- | (244.77M) | (53.58M) | (95.82M) | (130.93M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
- | (244.77M) | (53.58M) | (95.82M) | (130.93M) | |
Net Income Growth |
- | - | 78.11% | -78.86% | -36.64% | |
Net Margin Growth |
- | - | - | - | -2,518.41% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
- | (244.77M) | (53.58M) | (95.82M) | (130.93M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
- | (244.77M) | (53.58M) | (95.82M) | (130.93M) | |
EPS (Basic) |
- | - | - | (1.74) | (2.27) | |
EPS (Basic) Growth |
- | - | - | - | -30.13% | |
Basic Shares Outstanding |
- | - | - | 55.01M | 57.76M | |
EPS (Diluted) |
- | - | - | (1.74) | (2.27) | |
EPS (Diluted) Growth |
- | - | - | - | -30.13% | |
Diluted Shares Outstanding |
- | - | - | 55.01M | 57.76M | |
EBITDA |
- | (19.78M) | (47.77M) | (90.3M) | (113.76M) | |
EBITDA Growth |
- | - | -141.48% | -89.02% | -25.98% | |
EBITDA Margin |
- | - | - | - | -2,188.11% | NA |